The Gut Microbiota-Parkinson’s Disease Nexus: A Comprehensive Review on Dysbiosis, Nutrition, and Neurodegeneration
The loss of dopaminergic neurons is the hallmark of Parkinson’s Disease (PD), a progressive neurodegenerative illness that mostly impairs motor function. According to new research, the gut-brain axis and gut bacteria are key players in the pathophysiology of Parkinson’s disease. An imbalance in the makeup of gut microbes, known as dysbiosis, accelerates the progression of disease by causing neuroinflammation, α-synuclein aggregation, and increased intestinal permeability. Oxidative stress, mitochondrial dysfunction, and immunological dysregulation result from a decrease in bacteria that produce Short-Chain Fatty Acids (SCFAs) and an increase in pro-inflammatory microorganisms. The composition of the gut microbiota is greatly influenced by dietary factors; diets high in fiber encourage the generation of SCFA and have anti-inflammatory properties, whereas diets heavy in fat or processed foods worsen dysbiosis. Prebiotics, probiotics, and foods high in polyphenols are examples of nutritional therapies that may help reestablish microbial equilibrium and lessen the symptoms of Parkinson’s disease. Furthermore, diet-based therapy and Fecal Microbiota Transplantation (FMT) are becoming recognized as viable approaches to delay the progression of the disease. A potential biomarker for early Parkinson’s disease identification and disease monitoring is gut microbiota profiling. The potential of dietary therapies that target the gut microbiota in the management of Parkinson’s disease is highlighted in this review, which examines the relationship between gut microbiota, nutrition, and PD.